The immuno-oncology drug Opdivo will be available for use as a first-line treatment, and the administration subjects for Imbruvica and G-CSF injections will be expanded.

The Health Insurance Review and Assessment Service started collecting opinions on the amendment of the reimbursement standards that contain the changes above from the 24th.

The adjusted reimbursement standards will be implemented on September 1st.

Like the NCCN guidelines, Opdivo will be reimbursed as first-line treatment for HER 2-negative, unresectable, locally advanced, or metastatic gastric cancer.

Reimbursement will be approved for the combination treatment (first-line, palliative therapy